AZN: Q2 call - Focus remains on H2 pipeline

Research evidence excerpt

AZN: Q2 call - Focus remains on H2 pipeline

Marjan Daeipour - Specialist Sales - European Healthcare AC (44 20) 7134-1329 Europe Specialist Sales J P M O R G A Nmarjan.daeipour@jpmorgan.com

J.P. Morgan Securities plc 27 July 2026

This communication is intended for institutional and selected professional clients of J.P. Morgan only. Do not forward outside of your own organization.

You are receiving this email because you are a client of J.P. Morgan. If you would like to stop receiving the Healthcare Sector Specialist Commentary please email Marjan Daeipour at

marjan.daeipour@jpmorgan.com.

This material has been prepared by personnel in the Sales & Trading Department and may include non-independent research (investment recommendations) which, for the purposes of MiFID 2

compliance, may also constitute a marketing communication. As such, this material has not been prepared in accordance with legal requirements designed to promote the independence of Investment

Research, including but not limited to the prohibition on dealing ahead of the dissemination of Investment Research. It is not a product of J.P. Morgan’s Research Department. It is not a research report,

investment research or independent research and is not intended as such. This material is subject to the disclosures available at the following site http://www.jpmorgan.com/pages/disclosures/

materialdisclaimer The location of the natural person that produced this/these recommendation(s) (the Recommendation(s)) is set out in their signature block. Where the natural person that produced this

Recommendation(s) is located in EMEA the legal person involved in the production of the Recommendation is J.P. Morgan Securities plc (JPMS plc) a firm authorised by the Prudential Regulation